The University of Oxford started the Phase I trial of a novel mosaic vaccine targeting a “wide range” of HIV variations.
The HIV-CORE 0052 study, which is part of the European Aids Vaccine Initiative, will enroll 13 HIV-negative persons between the ages of 18 and 65 who are not deemed to be at high risk of infection.
The vaccination – known as the HIVconsvX vaccine –will be given to the participants once, followed by a booster dose four weeks later.
Lead researcher on the trial and professor of vaccine immunology at the Jenner Institute, University of Oxford Tomáš Hanke said that the HIV vaccine would be for prevention and cure.
“An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure,” he said.
He further said that there is strong evidence that undetectable HIV viral load prevents sexual transmission.
“Nevertheless, the pace of decline in new HIV infections failed to reach the Fast-Track Target agreed upon by the United Nations General Assembly in 2016: fewer than 500,000 new infections per year in 2020,” he said.
“Even in the broader context of increasing antiretroviral treatment and prevention, an HIV-1 vaccine remains the best solution and likely a key component to any strategy ending the AIDS epidemic,” he added.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.